Barclays
ELDN icon

Barclays’s Eledon Pharmaceuticals ELDN Stock Holding History

Barclays’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.6K Sell
13,816
-73,656
-84% -$173K ﹤0.01% 4380
2025
Q4 		$132K Buy
87,472
+7,719
+10% +$18.3K ﹤0.01% 4493
2025
Q3 		$207K Sell
79,753
-22,125
-22% -$64.7K ﹤0.01% 4272
2025
Q2 		$276K Buy
101,878
+31,878
+46% +$95.6K ﹤0.01% 4086
2025
Q1 		$237K Hold
70,000
– – ﹤0.01% 3947
2024
Q4 		$288K Buy
+70,000
New +$276K ﹤0.01% 4137
2019
Q2 		– Sell
-4
Closed – – 7007
2019
Q1 		$0 Buy
+4
New +$265 ﹤0.01% 7077
2018
Q4 		– Hold
0
– – – 7032
2018
Q3 		– Hold
0
– – – 7192
2018
Q2 		– Sell
-1
Closed -$103 – 7034
2018
Q1 		$0 Buy
+1
New +$74 ﹤0.01% 7123
2017
Q4 		– Hold
0
– – – 6962
2017
Q3 		– Sell
-3
Closed -$249 – 6890
2017
Q2 		$0 Sell
3
-73
-96% -$7.44K ﹤0.01% 6708
2017
Q1 		$10K Buy
76
+51
+204% +$7.49K ﹤0.01% 6069
2016
Q4 		$4K Buy
25
+19
+317% +$3.64K ﹤0.01% 6182
2016
Q3 		$1K Buy
6
+4
+200% +$1.46K ﹤0.01% 6381
2016
Q2 		$2K Buy
2
+1
+100% +$1.1K ﹤0.01% 5943
2016
Q1 		$1K Sell
1
-2
-67% -$1.96K ﹤0.01% 5956
2015
Q4 		$4K Buy
+3
New +$5.23K ﹤0.01% 5612
2015
Q3 		– Sell
-1
Closed -$2.06K – 6878
2015
Q2 		$2K Hold
1
– – ﹤0.01% 6790
2015
Q1 		$2K Sell
1
-2
-67% -$4.41K ﹤0.01% 6860
2014
Q4 		$7K Buy
+3
New +$7.12K ﹤0.01% 6875

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Barclays's ELDN Position: Q1 2026 in Review

Barclays reduced its Eledon Pharmaceuticals (ELDN) stake by 84% in Q1 2026, selling an estimated $173K and leaving 13,816 shares worth $42.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4380.

Barclays first reported a position in ELDN in Q4 2014 and has held it in 18 quarters since. The position peaked at $288K in Q4 2024. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Barclays held 13,816 shares of Eledon Pharmaceuticals worth $42.6K as of Q1 2026.
  • Barclays sold 73,656 Eledon Pharmaceuticals shares in Q1 2026, an estimated $173K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4380 holding.
  • Barclays first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 18 quarters since.
  • Barclays's Eledon Pharmaceuticals position peaked at $288K in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.